{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1361137045140389760.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1136/bjo.2009.159160"}},{"identifier":{"@type":"URI","@value":"https://syndication.highwire.org/content/doi/10.1136/bjo.2009.159160"}}],"dc:title":[{"@value":"Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials"}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1380004231233207683","@type":"Researcher","foaf:name":[{"@value":"P Mitchell"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137045140389766","@type":"Researcher","foaf:name":[{"@value":"J-F Korobelnik"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137045140389760","@type":"Researcher","foaf:name":[{"@value":"P Lanzetta"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137045140389762","@type":"Researcher","foaf:name":[{"@value":"F G Holz"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137045140389761","@type":"Researcher","foaf:name":[{"@value":"C Prunte"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137045140389767","@type":"Researcher","foaf:name":[{"@value":"U Schmidt-Erfurth"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137045140389763","@type":"Researcher","foaf:name":[{"@value":"Y Tano"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137045140389765","@type":"Researcher","foaf:name":[{"@value":"S Wolf"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"00071161"}],"prism:publicationName":[{"@value":"British Journal of Ophthalmology"}],"dc:publisher":[{"@value":"BMJ"}],"prism:publicationDate":"2009-05-13","prism:volume":"94","prism:number":"1","prism:startingPage":"2","prism:endingPage":"13"},"reviewed":"false","url":[{"@id":"https://syndication.highwire.org/content/doi/10.1136/bjo.2009.159160"}],"createdAt":"2009-05-15","modifiedAt":"2020-09-25","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1050012570394383104","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Effectiveness of intravitreal ranibizumab in exudative age-related macular degeneration (AMD): comparison between typical neovascular AMD and polypoidal choroidal vasculopathy over a 1 year follow-up"}]},{"@id":"https://cir.nii.ac.jp/crid/1360004231233207936","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Aqueous vascular endothelial growth factor and ranibizumab concentrations after monthly and bimonthly intravitreal injections of ranibizumab for age-related macular degeneration"}]},{"@id":"https://cir.nii.ac.jp/crid/1360283691080983552","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Subfoveal Choroidal Thickness during Aflibercept Therapy for Neovascular Age-Related Macular Degeneration"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285706926242176","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Combined Intravitreal Ranibizumab and Photodynamic Therapy for Retinal Angiomatous Proliferation"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285710470271872","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Aqueous vascular endothelial growth factor and aflibercept concentrations after bimonthly intravitreal injections of aflibercept for age‐related macular degeneration"}]},{"@id":"https://cir.nii.ac.jp/crid/1360302470019014912","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"First-year real-world experience of intravitreal brolucizumab injection for refractory neovascular age-related macular degeneration"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567181267790080","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Subfoveal choroidal thickness in polypoidal choroidal vasculopathy after switching to intravitreal aflibercept injection"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567182365305984","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Treatment Patterns and Health Care Costs for Age-Related Macular Degeneration in Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567185705875840","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Long‐term efficacy and safety of ranibizumab administered <i>pro re nata</i> in Japanese patients with neovascular age‐related macular degeneration in the EXTEND‐I study"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848661270106624","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Early Responses to Intravitreal Ranibizumab in Typical Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy"}]},{"@id":"https://cir.nii.ac.jp/crid/1361131421003250048","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Genetic biomarkers in the VEGF pathway predicting response to anti-VEGF therapy in age-related macular degeneration"}]},{"@id":"https://cir.nii.ac.jp/crid/1363104598394285312","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Two-year results of combined intravitreal anti-VEGF agents and photodynamic therapy for retinal angiomatous proliferation"}]},{"@id":"https://cir.nii.ac.jp/crid/1523669555364359168","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"CLINICAL INVESTIGATION : Treatment results at 1 year of ranibizumab therapy for polypoidal choroidal vasculopathy in eyes with good visual acuity"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1136/bjo.2009.159160"},{"@type":"CROSSREF","@value":"10.1007/s00417-013-2505-2_references_DOI_a6YVFRpsjIrtqbgRDVrUBmNMEgk"},{"@type":"CROSSREF","@value":"10.1186/1471-2415-13-10_references_DOI_a6YVFRpsjIrtqbgRDVrUBmNMEgk"},{"@type":"CROSSREF","@value":"10.1111/ceo.13002_references_DOI_a6YVFRpsjIrtqbgRDVrUBmNMEgk"},{"@type":"CROSSREF","@value":"10.1007/s10384-024-01134-7_references_DOI_a6YVFRpsjIrtqbgRDVrUBmNMEgk"},{"@type":"CROSSREF","@value":"10.1007/s10384-015-0411-3_references_DOI_a6YVFRpsjIrtqbgRDVrUBmNMEgk"},{"@type":"CROSSREF","@value":"10.1111/j.1755-3768.2010.02065.x_references_DOI_a6YVFRpsjIrtqbgRDVrUBmNMEgk"},{"@type":"CROSSREF","@value":"10.1016/j.ophtha.2016.01.042_references_DOI_a6YVFRpsjIrtqbgRDVrUBmNMEgk"},{"@type":"CROSSREF","@value":"10.1155/2011/742020_references_DOI_a6YVFRpsjIrtqbgRDVrUBmNMEgk"},{"@type":"CROSSREF","@value":"10.1007/s10384-013-0245-9_references_DOI_a6YVFRpsjIrtqbgRDVrUBmNMEgk"},{"@type":"CROSSREF","@value":"10.1136/bmjophth-2019-000273_references_DOI_a6YVFRpsjIrtqbgRDVrUBmNMEgk"},{"@type":"CROSSREF","@value":"10.1016/j.ophtha.2015.10.039_references_DOI_a6YVFRpsjIrtqbgRDVrUBmNMEgk"},{"@type":"CROSSREF","@value":"10.1016/j.ajo.2011.08.038_references_DOI_a6YVFRpsjIrtqbgRDVrUBmNMEgk"},{"@type":"CROSSREF","@value":"10.1007/s10384-012-0215-7_references_DOI_a6YVFRpsjIrtqbgRDVrUBmNMEgk"}]}